Philips to Further Roll Out RATE: AI for Early Infection Detection at U.S. Department of Defense Through Four-Year, $25 Million Contract

Published a month ago via Business Wire

After successful development and pilot, groundbreaking technology using biomarkers from wearables to predict infection is set to expand within the DoD

Royal Philips (NYSE: PHG, AEX: PHIA) today announced it will accelerate the predictive health monitoring of the Rapid Analysis of Threat Exposure (RATE) algorithm to support the well-being and readiness of active-duty service personnel for the U.S. Department of Defense (DoD). Over the next four years, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), will invest $25 million to make the technology more accessible in the field.

RATE, in advanced development, is an early detector of pre-symptomatic infection in humans. It is part of efforts to improve the readiness monitoring of active-duty personnel and has broad application in healthcare settings. The algorithm was developed as an early warning system that can reduce an individual’s downtime and aid in quickly containing the spread of disease by allowing exposed individuals to self-isolate or seek medical attention sooner.

“Our mission is to protect our troops and ensure we can quickly detect and prevent the spread of illness that can impact their wellbeing and our ability to protect our nation,” said Lorenzo Hankla, JPEO Wearables Program Officer. “Giving them the option of using readily available off-the-shelf wearables that are trained on clinical data allows them to passively monitor their health and quickly act if their infection score is high. In the wake of the pandemic, our troops need access to new AI-enabled technologies that can have a meaningful impact on their readiness and ensure overall military operations.”

The first version of the RATE algorithm, developed in 2019, used large-scale data science, machine learning, and trade-space analyses across demographics and 163 different biomarkers (vital signs and laboratory measurements) from a rich Philips data set of over 36,000 cases of hospital-acquired infections to develop a risk score. The risk score worked for multiple general types of infection, including common respiratory infections like pneumococcal pneumonia. These results were published in a 2023 study in Frontiers in Medicine.

A wearable version of the algorithm, prompted by the COVID-19 pandemic, leveraged biometric data from commercial-off-the-shelf wearables to enable early detection of infection. A 2022 study published in Nature’s Scientific Reports showed how, in a cohort of 9,381 DoD personnel, the algorithm was able to detect COVID-19 infection on average 2.3 days before symptoms appeared and up to six days prior. The study highlighted the utilization of algorithm-powered wearables to aid military readiness.

“Protecting the physical health and well-being of active service members is paramount,” said Jeff DiLullo, Chief Region Leader, Philips North America, and U.S. Army Veteran. “Our military personnel have unique care needs depending on their role and environment, and thanks to AI-enabled, predictive innovations like RATE, we can enable more timely intervention and personalized care, reducing downtime and improving outcomes – not only for individuals but entire units, too. The faster we diagnose and treat, the sooner these brave men and women are ready for duty.”

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About the JPEO-CBRND:

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the joint force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the joint force to fight and win unencumbered by a CBRN environment. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.

Contacts